COMMUNIQUE FROM EXTRAORDINARY GENERAL MEETING IN SENZIME AB (PUBL)

The extraordinary general meeting in Senzime AB (publ), corp. reg. no 556565-5734 (the “Company”) was held on 31 August 2022 by voting in advance, whereby the shareholders primarily resolved on the following matter.

Board of directors

The general meeting resolved to, for the time until the end of the next annual general meeting, elect Laura Piccinini and Jenny E Freeman as members of the board of directors. Therefore, the board of directors will consist of chairman Philip Siberg and board members Adam Dahlberg, Eva Walde, Lennart Kalén, Sorin J. Brull, Laura Piccinini and Jenny E Freeman.

It was noted that all resolutions were unanimous.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB 
Phone: +46 (0) 70-813 34 17, e-mail: [email protected]
 
Slavoljub Grujicic, CFO
Phone: +46 46 (0) 76-306 60 11, e-mail: [email protected]

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). www.senzime.com

Downloads
Contact

Philip Siberg, CEO of Senzime

+46 (0) 70 790 6734
[email protected]
 

Subscribe

Click here to sign up to our latest news.

Subscription service
en sv de